J
Joseph Pearlberg
Researcher at Harvard University
Publications - 13
Citations - 2455
Joseph Pearlberg is an academic researcher from Harvard University. The author has contributed to research in topics: Kinase & Cell culture. The author has an hindex of 13, co-authored 13 publications receiving 2369 citations.
Papers
More filters
Journal ArticleDOI
Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification.
Morgan L. Maeder,Stacey Thibodeau-Beganny,Anna Osiak,David A. Wright,Reshma M. Anthony,Magdalena Eichtinger,Tao Jiang,Jonathan E. Foley,Ronnie J. Winfrey,Jeffrey A. Townsend,Erica Unger-Wallace,Jeffry D. Sander,Felix Müller-Lerch,Fengli Fu,Joseph Pearlberg,Carl Göbel,Justin P. Dassie,Shondra M. Pruett-Miller,Matthew H. Porteus,Dennis C. Sgroi,A. John Iafrate,Drena Dobbs,Paul B. McCray,Toni Cathomen,Daniel F. Voytas,J. Keith Joung +25 more
TL;DR: OP (Oligomerized Pool ENgineering), a rapid, publicly available strategy for constructing multifinger arrays, which is more effective than the previously published modular assembly method and provides an "open-source" method for rapidly engineering highly active zinc-finger arrays.
Journal ArticleDOI
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Jeffrey A. Engelman,Pasi A. Jänne,Craig H. Mermel,Joseph Pearlberg,Toru Mukohara,Christina Fleet,Karen Cichowski,Bruce E. Johnson,Lewis C. Cantley +8 more
TL;DR: ErbB-3 is used to couple EGFR to the PI3K/Akt pathway in gefitinib-sensitive NSCLC cell lines harboring WT and mutant EGFRs, and dissociates this complex, thereby linking EGFR inhibition to decreased Akt activity.
Journal ArticleDOI
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
Toru Mukohara,Jeffrey A. Engelman,N.H. Hanna,Beow Y. Yeap,Susumu Kobayashi,Neal I. Lindeman,Balazs Halmos,Balazs Halmos,Joseph Pearlberg,Zenta Tsuchihashi,Lewis C. Cantley,Daniel G. Tenen,Bruce E. Johnson,Pasi A. Jänne +13 more
TL;DR: Gefitinib treatment decreased EGFR, ERK1/2, and Akt phosphorylation in EGFR mutant cell lines whereas cetuximab had relatively little effect, and EGFR mutations in NSCLC cells are associated with sensitivity to gefit inib but not to cetUXimab.
Journal ArticleDOI
Contact with a component of the polymerase II holoenzyme suffices for gene activation.
Alcide Barberis,Joseph Pearlberg,Natasha Simkovich,Susan Farrell,Pamela Reinagel,Cynthia Bamdad,George Sigal,Mark Ptashne +7 more
TL;DR: It is proposed that a single activator-holoenzyme contact can trigger gene activation simply by recruiting the latter to DNA.
Journal ArticleDOI
Targeted Mutagenesis in Zebrafish Using Customized Zinc Finger Nucleases
Jonathan E. Foley,Morgan L. Maeder,Joseph Pearlberg,J. Keith Joung,Randall T. Peterson,Randall T. Peterson,Jing-Ruey J. Yeh +6 more
TL;DR: Using these methods, zebrafish founders carrying targeted mutations can be identified within 4 months, and the vectors and methods are compatible with previously described Zinc-Finger Consortium reagents for constructing engineered zinc-finger arrays.